mg/mL).DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or DDAVP is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of In certain clinical situations, it may be justified to try DDAVP in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored.DDAVP will usually stop bleeding in mild to moderate von Willebrand's patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.Those von Willebrand's disease patients who are least likely to respond are those with severe DDAVP is not indicated for the treatment of severe classic von Willebrand's *DDAVP should be administered 30 minutes prior to an invasive procedure in order to achieve maximum effectiveness. factor VIII antigen. Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment.
The factor VIII related antigen and ristocetin cofactor activity were also increased to a smaller degree, but still are dose-dependent.DDAVP is mainly excreted in the urine. (See DDAVP is also available as an intranasal preparation. Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.. It is not known whether this drug is excreted in human milk. restriction should be discussed with the patient. function. DDAVP side effects. DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min). Rev. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe renal impairment (n=24, 6 subjects in each group) receiving single dose desmopressin acetate (2 mcg) injection demonstrated a difference in DDAVP terminal half-life. For patients who have been controlled on intranasal DDAVP and who must be switched to the injection form, either because of poor intranasal absorption or because of the need for surgery, the comparable antidiuretic dose of the injection is about one-tenth the intranasal dose.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Other patients may respond in a variable fashion depending on the type of molecular defect they have. DDAVP Injection (desmopressin acetate) is a man-made form of a hormone that occurs naturally in the pituitary gland used to treat hemophilia A or von Willebrand's disease Type I, and is also used to treat central cranial diabetes insipidus, and increased thirst and urination caused by head surgery or head trauma.DDAVP Injection is available in generic form. If factor VIII coagulant activity is present at less than 5% of normal, DDAVP should not be relied on.Laboratory tests for assessing patient status include levels of factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand factor antigen. In some cases, plasma osmolality may be required.Although the pressor activity of DDAVP is very low compared with the antidiuretic activity, use of doses as large as 0.3 mcg/kg of DDAVP with other pressor agents should be done only with careful patient monitoring. Maximal dose response occurred at 0.3 to 0.4 mcg/kg. 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. function.

1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrateThe 10 mL vial contains chlorobutanol as a preservative (5 mg/mL).DDAVP has been shown to be more potent than arginine vasopressin in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand's disease Type I.Dose-response studies were performed in healthy persons, using doses of 0.1 to 0.4 mcg/kg body weight, infused over a 10-minute period. *Monitor blood pressure at start and completion of infusion. https://www.webmd.com/drugs/2/drug-6466/ddavp-injection/details A fifteen year, Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min).DDAVP is contraindicated in patients with hyponatremia or a history of hyponatremia.DDAVP (desmopressin acetate) should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, heart failure and renal disorders, because these patients are prone to hyponatremia.There have been rare reports of thrombotic events following Severe allergic reactions have been reported rarely. impairment (defined as a creatinine clearance below 50ml/min). DOSAGE AND ADMINISTRATION. restrictions to prevent possible hyponatremia and water intoxication. DDAVP ® /Desmopressin Injection does not reduce prolonged bleeding time in thrombocytopenia. Fluid restriction should be discussed with the patient and/or guardian. In adults and children weighing more than 10 kg, 50 mL of diluent is recommended; in children weighing 10 kg or less, 10 mL of diluent is recommended. The 10 mL vial contains chlorobutanol as a preservative (5.0 However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate.